MarketPulse

Type 1 diabetes

5 articles
BenzingaBenzinga··Globe Newswire

SAB Biotherapeutics Raises $85M to Advance Type 1 Diabetes Treatment

SAB Biotherapeutics prices $85M offering at $3.85/share to fund Phase 2b trials of type 1 diabetes candidate SAB-142, with closing expected March 2026.
SABSSABSWclinical trialpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

SAB Biotherapeutics Raises $85M to Accelerate Diabetes Drug Development

SAB Biotherapeutics prices $85M offering of shares and warrants to fund clinical trials for SAB-142, its lead type 1 diabetes candidate.
SABSSABSWclinical trialpublic offering
BenzingaBenzinga··Prnewswire

Global Diabetes Survey Reveals Market Gap: 80% Demand Predictive Tools Beyond CGM

Survey of 4,326 diabetics across 22 countries shows 80% demand predictive glucose forecasting tools, revealing unmet market need beyond current continuous glucose monitoring.
RHHBYhealthcare technologyType 1 diabetes
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Pharmaceuticals Outpaces Centessa With Established Revenue and Advanced Pipeline

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.
VRTXCNTAbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MannKind to Present at Oppenheimer Conference While Advancing Pediatric Diabetes Program

MannKind's CEO will present at Oppenheimer Conference on February 26 while the company enrolls first patient in pediatric diabetes trial for its Afrezza insulin therapy.
MNKDQ4 2025 financial resultsbiopharmaceutical